82 related articles for article (PubMed ID: 24239883)
41. PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Pinton G; Manente AG; Murer B; De Marino E; Mutti L; Moro L
J Cell Mol Med; 2013 Feb; 17(2):233-41. PubMed ID: 23301673
[TBL] [Abstract][Full Text] [Related]
42. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
Geng H; Rademacher BL; Pittsenbarger J; Huang CY; Harvey CT; Lafortune MC; Myrthue A; Garzotto M; Nelson PS; Beer TM; Qian DZ
Cancer Res; 2010 Apr; 70(8):3239-48. PubMed ID: 20388787
[TBL] [Abstract][Full Text] [Related]
43. MCL-1 dependency of cisplatin-resistant cancer cells.
Michels J; Obrist F; Vitale I; Lissa D; Garcia P; Behnam-Motlagh P; Kohno K; Wu GS; Brenner C; Castedo M; Kroemer G
Biochem Pharmacol; 2014 Nov; 92(1):55-61. PubMed ID: 25107702
[TBL] [Abstract][Full Text] [Related]
44. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
45. [Molecular mechanisms of regulaion of transcription by PARP1].
Maliuchenko NV; Kulaeva OI; Kotova E; Chupyrkina AA; Nikitin DV; Kirpichnikov MP; Studitskiĭ VM
Mol Biol (Mosk); 2015; 49(1):99-113. PubMed ID: 25916114
[TBL] [Abstract][Full Text] [Related]
46. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
47. Probing PARP1-inhibitor complexes for the development of novel inhibitors.
Saqib U; Baig MS
Cell Mol Biol (Noisy-le-grand); 2014 Oct; 60(3):43-52. PubMed ID: 25346248
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Tang Y; Wang YL; Yang L; Xu JX; Xiong W; Xiao M; Li M
Int J Mol Med; 2013 Jul; 32(1):130-6. PubMed ID: 23652727
[TBL] [Abstract][Full Text] [Related]
49. Poly (ADP-ribose) polymerase-1: an emerging target in right ventricle dysfunction associated with pulmonary hypertension.
Kaur G; Singh N; Lingeshwar P; Siddiqui HH; Hanif K
Pulm Pharmacol Ther; 2015 Feb; 30():66-79. PubMed ID: 25481773
[TBL] [Abstract][Full Text] [Related]
50. Oncogenic miR-9 is a target of erlotinib in NSCLCs.
Chen X; Zhu L; Ma Z; Sun G; Luo X; Li M; Zhai S; Li P; Wang X
Sci Rep; 2015 Nov; 5():17031. PubMed ID: 26593208
[TBL] [Abstract][Full Text] [Related]
51. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
52. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress.
Módis K; Gero D; Erdélyi K; Szoleczky P; DeWitt D; Szabo C
Biochem Pharmacol; 2012 Mar; 83(5):633-43. PubMed ID: 22198485
[TBL] [Abstract][Full Text] [Related]
53. Poly(
Yang Y; Kozlovskaya V; Zhang Z; Xing C; Zaharias S; Dolmat M; Qian S; Zhang J; Warram JM; Yang ES; Kharlampieva E
ACS Appl Bio Mater; 2022 Apr; 5(4):1670-1682. PubMed ID: 35294185
[TBL] [Abstract][Full Text] [Related]
54. Stress response: PARP1 911.
Bock FJ; Chang P
Nat Chem Biol; 2015 Mar; 11(3):179-80. PubMed ID: 25689334
[No Abstract] [Full Text] [Related]
55. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Oct; 22(10):1192. PubMed ID: 27711065
[No Abstract] [Full Text] [Related]
56. Novel Azaquinolones as PARP1 Inhibitors for Treating Cancer.
Sabnis RW
ACS Med Chem Lett; 2021 Apr; 12(4):524-525. PubMed ID: 33859786
[No Abstract] [Full Text] [Related]
57. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Nomura H; Kataoka F; Aoki D; Jinno H; Kitagawa Y; Sato Y; Womack C; Wombwell H; Hodgson D; O'Connor M; Harbron C; Yin X
Cancer Biomark; 2016; 16(1):145-52. PubMed ID: 26577420
[TBL] [Abstract][Full Text] [Related]
58. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
59. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
60. Maintenance therapy in ovarian cancer.
Khalique S; Hook JM; Ledermann JA
Curr Opin Oncol; 2014 Sep; 26(5):521-8. PubMed ID: 25033374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
